<DOC>
	<DOCNO>NCT01718899</DOCNO>
	<brief_summary>The purpose study determine safety tolerability PVX-410 , ( cancer vaccine ) , treatment regimen patient smolder multiple myeloma single agent combination lenalidomide .</brief_summary>
	<brief_title>Phase 1/2a Study Cancer Vaccine Treat Smoldering Multiple Myeloma</brief_title>
	<detailed_description>This dose escalation , phase 1/2a study ass safety tolerability PVX-410 , ( multi-peptide cancer vaccine ) , treatment regimen patient smolder multiple myeloma single agent combination lenalidomide.. Approximately 22 patient receive six ( 6 ) bi-weekly , subcutaneous injection PVX-410 total twelve ( 12 ) week treatment . Safety monitor throughout study . Tolerability , immunogenicity clinical response also measure describe protocol .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<criteria>Patient confirm clinical diagnosis SMM accord definition derive International Myeloma Working Group ( IMWG ) definition : serum Mprotein ≥3 g/dL bone marrow clonal plasma cell ( BMPC ) great equal 10 % , , along normal organ marrow function ( CRAB ) within 4 week baseline . C : Absence hypercalcemia , evidence calcium &lt; 10.5 mg/dL . R : Absence renal failure , evidence creatinine &lt; 2.0 mg/dL calculate creatinine clearance ( use Modification Diet Renal Disease [ MDRD ] formula ) &gt; 50 mL/min . A : Absence anemia , evidence hemoglobin &gt; 10 g/dL . B : Absence lytic bone lesion standard skeletal survey . Patient high average risk progression active MM , define 2 follow feature : Serum monoclonal ( M ) protein ≥3 g/dL . BMPC great equal 10 % . Abnormal serum free light chain ( FLC ) ratio ( 0.261.65 ) . Patient life expectancy great 6 month Patient human leukocyte antigen ( HLA ) A2 positive . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patient adequate bone marrow function , evidence platelet count ≥75×109/L absolute neutrophil count ( ANC ) ≥1.0×109/L within 2 week baseline . Patient adequate hepatic function , evidence bilirubin ≤2.0 mg/dL alanine transaminase ( ALT ) , aspartate transaminase ( AST ) ≤2.5× upper limit normal ( ULN ) within 2 week baseline . If childbearing potential , patient agrees use adequate birth control measure study participation . If female childbearing potential , patient negative urine pregnancy test result within 2 week baseline lactating . Patient ( legally accept representative ) provide write informed consent participate study . Patient symptomatic multiple myeloma , define follow : Lytic lesion pathologic fracture . Anemia ( hemoglobin &lt; 10 g/dL ) . Hypercalcemia ( correct serum calcium &gt; 11.5 mg/dL ) . Renal insufficiency ( creatinine &gt; 2 mg/dL ) . Other : symptomatic hyperviscosity , amyloidosis . Patient abnormal cardiac status , evidence follow : New York Heart Association ( NYHA ) stage III IV congestive heart failure ( CHF ) . Myocardial infarction within previous 6 month . Symptomatic cardiac arrhythmia require treatment persist despite treatment . Patient receive investigational agent . Patient current active infectious disease positive serology human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) . Patient history current autoimmune disease . Patient vaccinate live attenuate vaccine within 4 week study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>